Pharma
The randomized controlled trial of the jointly-developed digital therapeutics will be conducted using Verily's Project Baseline and enroll up to 540 patients.
The partnership will be looking to use AliveCor's Kardia-K AI, which is designed to measure a patient's potassium levels.
The solution uses AI and machine learning to improve adherence.
MobiHealthNews spoke with Pear Therapeutics, Click Therapeutics and DTx newcomer Mahana Therapeutics to discuss whether in-licensing is the way to go for those just entering the space.
Also: Kaiser Permanente doubles down on the cloud with Accenture and Microsoft; Boehringer Ingelheim arms its reps with BreezoMeter's air quality data.
Flare Capital's Alexandra Mullin and Ian Chiang outline COVID-19's impact on the worsening opioid crisis and how the digital opioid use disorder space is likely to develop over the coming years.
Also: Blood glucose monitoring could be coming to next-gen consumer smartwatches; new incubator looking for disruptive health tech startups.
Asset Management Ventures' Skip Fleshman outlines COVID-19's impact on clinical trials and the resulting leap toward tech-enabled decentralized trials.
The pair will meet quarterly to discuss possible integrations and collaborations with the pharma industry.